Literature DB >> 18350576

Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers.

Delia M Talos1, David J Kwiatkowski, Kathia Cordero, Peter M Black, Frances E Jensen.   

Abstract

OBJECTIVE: Genetic loss of TSC1/TSC2 function in tuberous sclerosis complex (TSC) results in overactivation of the mammalian target of rapamycin complex 1 pathway, leading to cellular dysplasia. We hypothesized that the dysplastic cells in TSC tubers are heterogeneous, including separable classes on a neuronal-glial spectrum, and that these dysplastic cells express glutamate receptor (GluR) patterns consistent with increased cortical network excitability.
METHODS: Surgically resected human cortical tubers and nondysplastic epileptic cortical samples were analyzed by double-label immunocytochemistry for coexpression of neuronal and glial markers, the TSC1/TSC2 pathway downstream molecule phospho-S6 (pS6) and GluR subunits, and compared with control cortical tissue. Western blotting was used to quantify changes in GluR subunit expression in tubers versus controls.
RESULTS: We demonstrate that cortical tubers contain a broad spectrum of cell types including disoriented pyramidal cells, dysplastic neurons, giant neuroglial cells, dysplastic astroglia, and reactive astrocytes. Dysplastic neurons, giant cells, and dysplastic astroglia express high levels of pS6 and demonstrate altered GluR subunit composition, resembling those of normal immature neurons and glia. In contrast, nondysplastic neurons in TSC and non-TSC epileptic lesions express lower pS6 levels and display changes in GluR subunit expression that are distinct from the patterns seen in tuber dysplastic cells.
INTERPRETATION: This work significantly expands the spectrum of abnormal cells recognized in tubers beyond the classic tuber giant cell and demonstrates cell-specific abnormalities in GluR expression that may contribute to seizure pathogenesis in TSC. Furthermore, these results suggest that subunit-specific antagonists may be of potential use in the treatment of epilepsy in TSC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18350576      PMCID: PMC2701384          DOI: 10.1002/ana.21342

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  49 in total

1.  Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes.

Authors:  Laura A Jansen; Erik J Uhlmann; Peter B Crino; David H Gutmann; Michael Wong
Journal:  Epilepsia       Date:  2005-12       Impact factor: 5.864

Review 2.  Developmental factors regulating susceptibility to perinatal brain injury and seizures.

Authors:  Frances E Jensen
Journal:  Curr Opin Pediatr       Date:  2006-12       Impact factor: 2.856

Review 3.  Epileptogenesis in pediatric cortical dysplasia: the dysmature cerebral developmental hypothesis.

Authors:  Carlos Cepeda; Véronique M André; Michael S Levine; Noriko Salamon; Hajime Miyata; Harry V Vinters; Gary W Mathern
Journal:  Epilepsy Behav       Date:  2006-07-27       Impact factor: 2.937

4.  Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex.

Authors:  Delia M Talos; Pamela L Follett; Rebecca D Folkerth; Rachel E Fishman; Felicia L Trachtenberg; Joseph J Volpe; Frances E Jensen
Journal:  J Comp Neurol       Date:  2006-07-01       Impact factor: 3.215

5.  Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography.

Authors:  K Zilles; M S Qü; R Köhling; E J Speckmann
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

6.  Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia.

Authors:  M Cecilia Ljungberg; Meenakshi B Bhattacharjee; Yaojuan Lu; Dawna L Armstrong; Daniel Yoshor; John W Swann; Michael Sheldon; Gabriella D'Arcangelo
Journal:  Ann Neurol       Date:  2006-10       Impact factor: 10.422

7.  The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.

Authors:  R F Lamb; C Roy; T J Diefenbach; H V Vinters; M W Johnson; D G Jay; A Hall
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

8.  A common pattern of persistent gene activation in human neocortical epileptic foci.

Authors:  Sanjay N Rakhade; Bin Yao; Sharlin Ahmed; Eishi Asano; Thomas L Beaumont; Aashit K Shah; Sorin Draghici; Raul Krauss; Harry T Chugani; Sandeep Sood; Jeffrey A Loeb
Journal:  Ann Neurol       Date:  2005-11       Impact factor: 10.422

Review 9.  Molecular signaling mechanisms underlying epileptogenesis.

Authors:  James O McNamara; Yang Zhong Huang; A Soren Leonard
Journal:  Sci STKE       Date:  2006-10-10

10.  Cytomegalic interneurons: a new abnormal cell type in severe pediatric cortical dysplasia.

Authors:  Véronique M André; Nanping Wu; Irene Yamazaki; Snow T Nguyen; Robin S Fisher; Harry V Vinters; Gary W Mathern; Michael S Levine; Carlos Cepeda
Journal:  J Neuropathol Exp Neurol       Date:  2007-06       Impact factor: 3.685

View more
  46 in total

1.  Tuber-Less Models of Tuberous Sclerosis Still Provide Insights Into Epilepsy.

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2015 May-Jun       Impact factor: 7.500

2.  Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.

Authors:  Vinit V Patil; Miguel Guzman; Angela N Carter; Geetanjali Rathore; Daniel Yoshor; Daniel Curry; Angus Wilfong; Satish Agadi; John W Swann; Adekunle M Adesina; Meenakshi B Bhattacharjee; Anne E Anderson
Journal:  Neuropathology       Date:  2015-09-18       Impact factor: 1.906

Review 3.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 4.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

5.  A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

Authors:  Emmanuel Raffo; Antonietta Coppola; Tomonori Ono; Stephen W Briggs; Aristea S Galanopoulou
Journal:  Neurobiol Dis       Date:  2011-04-12       Impact factor: 5.996

6.  Enhanced GABAergic network and receptor function in pediatric cortical dysplasia Type IIB compared with Tuberous Sclerosis Complex.

Authors:  Carlos Cepeda; Véronique M André; Jason S Hauptman; Irene Yamazaki; My N Huynh; Julia W Chang; Jane Y Chen; Robin S Fisher; Harry V Vinters; Michael S Levine; Gary W Mathern
Journal:  Neurobiol Dis       Date:  2011-08-23       Impact factor: 5.996

Review 7.  Inflammation in Epileptic Encephalopathies.

Authors:  Oleksii Shandra; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Adv Protein Chem Struct Biol       Date:  2017-02-28       Impact factor: 3.507

8.  Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.

Authors:  Delia M Talos; Hongyu Sun; Bela Kosaras; Annelise Joseph; Rebecca D Folkerth; Annapurna Poduri; Joseph R Madsen; Peter M Black; Frances E Jensen
Journal:  Ann Neurol       Date:  2012-03-23       Impact factor: 10.422

9.  AMPA receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures.

Authors:  Jocelyn J Lippman-Bell; Sanjay N Rakhade; Peter M Klein; Makram Obeid; Michele C Jackson; Annelise Joseph; Frances E Jensen
Journal:  Epilepsia       Date:  2013-10-01       Impact factor: 5.864

Review 10.  A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Authors:  David M Feliciano; Tiffany V Lin; Nathaniel W Hartman; Christopher M Bartley; Cathryn Kubera; Lawrence Hsieh; Carlos Lafourcade; Rachel A O'Keefe; Angelique Bordey
Journal:  Int J Dev Neurosci       Date:  2013-02-26       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.